These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12564613)

  • 1. Conclusion. Lessons from the novel D2 dopamine receptor, beta2-adrenoceptor agonist, Viozan: chronic obstructive pulmonary disease and drug development implications.
    Calverley P; Keating ET; Goldman M; Casty F
    Respir Med; 2003 Jan; 97 Suppl A():S71-4. PubMed ID: 12564613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS).
    Celli B; Halpin D; Hepburn R; Byrne N; Keating ET; Goldman M
    Respir Med; 2003 Jan; 97 Suppl A():S35-43. PubMed ID: 12564609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, beta2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms.
    Ind PW; Laitinen L; Laursen L; Wenzel S; Wouters E; Deamer L; Nystrom P
    Respir Med; 2003 Jan; 97 Suppl A():S9-21. PubMed ID: 12564607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation.
    Laursen LC; Lindqvist A; Hepburn T; Lloyd J; Perrett J; Sanders N; Rocchiccioli K
    Respir Med; 2003 Jan; 97 Suppl A():S23-33. PubMed ID: 12564608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual dopamine D2 receptor and beta2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease: the pre-clinical rationale.
    Dougall IG; Young A; Ince F; Jackson DM
    Respir Med; 2003 Jan; 97 Suppl A():S3-7. PubMed ID: 12564606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term use of Viozan (sibenadet HCl) in patients with chronic obstructive pulmonary disease: results of a 1-year study.
    Hiller FC; Alderfer V; Goldman M
    Respir Med; 2003 Jan; 97 Suppl A():S45-52. PubMed ID: 12564610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of health care services by patients with chronic obstructive pulmonary disease.
    O'Brien JA; Ward AJ; Jones MK; McMillan C; Lordan N
    Respir Med; 2003 Jan; 97 Suppl A():S53-8. PubMed ID: 12564611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucociliary clearance in COPD can be increased by both a D2/beta2 and a standard beta2 agonists.
    Hasani A; Toms N; Agnew JE; Lloyd J; Dilworth JP
    Respir Med; 2005 Feb; 99(2):145-51. PubMed ID: 15715181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition by viozan of extravasation induced in rat trachea by capsaicin is mediated exclusively by beta 2-adrenoceptors.
    Fozard JR; Baur F; Wolber C; Collingwood SP
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):570-2. PubMed ID: 11770013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype.
    Lee JH; Lee YK; Kim EK; Kim TH; Huh JW; Kim WJ; Lee JH; Lee SM; Lee S; Lim SY; Shin TR; Yoon HI; Sheen SS; Kim N; Seo JB; Oh YM; Lee SD
    Respir Med; 2010 Apr; 104(4):542-9. PubMed ID: 19926461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials.
    Park J; Lee JS; Rhee C; Oh YM
    J Korean Med Sci; 2015 Oct; 30(10):1453-8. PubMed ID: 26425042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients.
    Mroz RM; Minarowski L; Chyczewska E
    Adv Exp Med Biol; 2013; 756():23-8. PubMed ID: 22836615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
    Sin DD; Man SF
    Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological approaches to stable chronic obstructive pulmonary disease.
    Booker R
    Br J Nurs; 2004 Oct 28-Nov 10; 13(19):1130-4. PubMed ID: 15573005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
    Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
    Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale.
    Leidy NK; Schmier JK; Jones MK; Lloyd J; Rocchiccioli K
    Respir Med; 2003 Jan; 97 Suppl A():S59-70. PubMed ID: 12564612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent advances in study of long β(2)-adrenoceptor agonist].
    Ge XY; Mo YM; Pan L; Cheng MS
    Yao Xue Xue Bao; 2016 Dec; 51(12):1838-44. PubMed ID: 29908535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute bronchodilator responses to β2-agonist and anticholinergic agent in COPD: Their different associations with exacerbation.
    Konno S; Makita H; Suzuki M; Shimizu K; Kimura H; Kimura H; Nishimura M;
    Respir Med; 2017 Jun; 127():14-20. PubMed ID: 28502414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R; Norris V; Siederer S
    Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
    Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
    Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.